MedPath

TiLE (Time Lapse Eeva) Clinical Trial

Phase 4
Completed
Conditions
Fertility
Interventions
Device: Eeva
Registration Number
NCT02417441
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Brief Summary

The purpose of the study was to explore the added value of adjunctive use of Early Embryo Viability Assessment (Eeva) with morphological grading in identifying optimal embryos for transfer.

Detailed Description

This study is a Phase IV, open label, prospective, randomized, exploratory, multicenter study. Subjects were randomized in 2:1 ratio to two treatment groups: in the experimental group, embryos were assessed for embryo transfer (ET) with Eeva and morphological grading, while in the control group embryos were assessed with morphological grading only.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
976
Inclusion Criteria
  • All infertile subjects treated with In vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI)
  • Subject age less than or equal to (<=) 40 years
  • Less than or equal to (<=) 3 failed IVF/ICSI cycles
  • At least 4 normally fertilized eggs (2 pronuclei [2PN]) in current cycle
  • Normal uterine cavity
  • Fertilization using only ejaculated sperm (fresh or frozen)
  • Subject must have read and signed the Informed Consent Form
Exclusion Criteria
  • Have clinically significant systemic disease
  • Have abnormal, undiagnosed gynecological bleeding
  • Have any contraindication to Controlled Ovarian Stimulation (COS) for assisted reproductive technologies (ART) and to gonadotropins to be used in ART
  • Egg donor cycle
  • Planned "freeze all" cycle (oocytes or embryos)
  • Concurrent participation in another clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Early Embryo Viability Assessment + Morphological GradingEevaEmbryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
Primary Outcome Measures
NameTimeMethod
Implantation RateGestational Weeks 5 to 8

Implantation rate was calculated by dividing the number of intrauterine gestational sacs by the number of embryos transferred multiplied by 100.

Secondary Outcome Measures
NameTimeMethod
Clinical Pregnancy RateGestational Weeks 5 to 8

Clinical pregnancy was confirmed by the presence of a gestational sac with heartbeat as assessed by ultrasonography. Clinical pregnancy rate was measured as the number of clinical pregnancies divided by number of embryo transfer (ET) cycles multiplied by 100.

Number of Subjects With Ongoing Pregnancy StatusGestational Weeks 10 to 12

Ongoing pregnancy was defined as having a positive fetal heart beat (FHB) as assessed by ultrasonography at gestational week 10-12. Number of subjects with ongoing pregnancy status has been reported, where "Yes" indicates participants with positive ongoing pregnancy status and "No" indicates participants with negative ongoing pregnancy status .

Multiple Pregnancy RateGestational Weeks 5 to 8

Multiple pregnancy rate was defined as a clinical pregnancy with greater than equals to (\>=) 2 fetal sacs as assessed by ultrasonography. Multiple Pregnancies rate was measured by number of multiple pregnancies divided by number of embryo transfer cycles multiplied by 100.

Utilization RateDay 3 or Day 5/6 of embryo culture

Utilization rate was defined as the sum of number of transferred and frozen embryos divided by number of normally fertilized oocytes multiplied by 100.

Spontaneous Miscarriage RateGestational Weeks 10 to 12

Spontaneous miscarriage rate was measured by the number of spontaneous miscarriages as communicated during medical appointment or by telephone contact divided by number of clinical pregnancies multiplied by 100.

Trial Locations

Locations (23)

One Fertility

🇨🇦

Burlington, Ontario, Canada

Cambrian Wellness Centre

🇨🇦

Calgary, Alberta, Canada

Mount Sinai Hospital

🇨🇦

Toronto, Canada

CHRU - Hopital Jeanne de Flandres

🇫🇷

Lille Cedex, France

Universitatsklinik Schleswig-Holstein

🇩🇪

Luebeck, Germany

Laboratoire Alphabio & Institut de Médecine de la Reproducti

🇫🇷

Marseille, France

MVZ Kinderwunschzentrum Wiesbaden GmbH

🇩🇪

Wiesbaden, Germany

Kinderwunsch Centrum München

🇩🇪

Munich, Germany

Telemark hospital Porsgrunn

🇳🇴

Skien, Norway

Montichiari Università degli studi di Bresca

🇮🇹

Montichiari, Italy

Ospedale Versilia

🇮🇹

Viareggio, Italy

Clinica Sagrada Familia

🇪🇸

Barcelona, Spain

Fertilitetscentrum Stockholm

🇸🇪

Stockholm, Sweden

Hospital Universitario Virgen de las Nieves

🇪🇸

Granada, Spain

Bourn Hall

🇬🇧

Cambridge, United Kingdom

Birmingham Women's Health Care NHS Trust

🇬🇧

Edgbaston, United Kingdom

Rigshospitalet

🇩🇰

Copenhagen, Denmark

Università degli Studi Torino

🇮🇹

Torino, Italy

Homerton University Hospital

🇬🇧

London, United Kingdom

Hopital Hotel Dieu

🇫🇷

Nantes, France

Istituto Clinico Humanitas

🇮🇹

Rozzano, Italy

Clínica Vistahermosa

🇪🇸

Alicante, Spain

ISIS Regional Fertility Clinic

🇨🇦

Mississauga, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath